Real world feasibility of combining pembrolizumab with radiotherapy in early triple negative breast cancer
Our findings show that concurrent RT and pembrolizumab is feasible with manageable toxicities, providing valuable support for clinicians in real-world practice beyond the selective context of clinical trials.
Authors
- Serena Di Cosimo (ORCID: https://orcid.org/0000-0002-4666-8052)
- Emanuele Pignoli
- Eliana La Rocca (ORCID: https://orcid.org/0000-0002-6783-710X)
- Maria Carmen De Santis (ORCID: https://orcid.org/0000-0003-3131-3969)
- Chiara Listorti (ORCID: https://orcid.org/0000-0003-4553-0817)
- Riccardo Lobefaro (ORCID: https://orcid.org/0000-0003-3484-9718)
- Riccardo Ray Colciago (ORCID: https://orcid.org/0000-0002-3867-2844)
- Daniele Presti (ORCID: https://orcid.org/0000-0003-4442-6700)
- Maria Grazia Carnevale (ORCID: https://orcid.org/0000-0003-3251-0139)
- Carlotta Giandini (ORCID: https://orcid.org/0009-0006-5544-8015)
- Laura Lozza (ORCID: https://orcid.org/0000-0002-7413-7427)
- Anna Cavallo (ORCID: https://orcid.org/0000-0002-8780-0734)
Institutions
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Ospedale A. Perrino (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- European Institute of Oncology (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1007/s12672-025-03172-0
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00